Print

Angiogen Release: Founder Of Biopharm Startup Publishes Results Of Clinical Cancer Research 
10/19/2005 5:11:39 PM

CHICAGO, Oct. 3 /PRNewswire/ -- Angiogen announced today that Dr. Gerald Soff, its Founder and Chief Scientific Officer, is the lead author of an article published in the September 1, 2005 issue of Clinical Cancer Research (Vol. 11, 6218-6225). The article, entitled In vivo Generation of Angiostatin Isoforms by Administration of a Plasminogen Activator and a Free Sulfhydryl Donor: A Phase I Study of an Angiostatic Cocktail of Tissue Plasminogen Activator and Mesna focuses on the results of a clinical study undertaken by Angiogen of its novel anti-angiogenic cancer therapy.

About Angiogen

Angiogen is an Evanston, Illinois based privately held biopharmaceutical discovery company developing novel therapies for treating cancerous solid, vascular tumors. Angiogen's scientific team has world-recognized expertise and experience in angiogenesis inhibition, especially as it relates to the disease of cancer. Angiogen's first therapy, currently in Phase IB/II clinical trials, is based upon combining two classes of FDA approved drugs into one anti-angiogenesis cancer-fighting treatment. Three major biopharmaceutical companies have provided support for Angiogen's clinical research to date. Angiogen continues to explore other diagnostic tests and drug candidates related to its work in angiogenesis field offering hope to the approximately 5 million people worldwide who will die annually from metastatic cancer (555,000 in US). For additional information on Angiogen, please visit our website at: http://www.angiogenesis.com .

About Clinical Cancer Research

Clinical Cancer Research is published twice monthly by the American Association for Cancer Research, Inc. (AACR). The journal publishes original articles describing clinical research on the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer. Clinical Cancer Research is especially interested in clinical trials evaluating new treatments for cancer. All submissions undergo peer review. For additional information, please telephone: 1-866-423-3965 or visit the web site at: http://clincancerres.aacrjournals.org .

This press release contains forward-looking statements that involve a high degree of technological, regulatory, and competitive risks and uncertainties inherent in early stage biopharmaceutical companies.

Angiogen

CONTACT: Dorene Lynch, +1-847-754-7815, fax, +1-847-864-3291 or email,dlynch@angiogenesis.com , for Angiogen


//-->